Skip to main content

Day: July 15, 2025

Aalberts reports the progress of its share buyback programme 07 July – 11 July 2025

Aalberts today reports that it has repurchased 2,500 of its own shares in the period from 07 July 2025, up to and including 11 July 2025, for an amount of EUR 78,823.16, so at an average share price of EUR 31.53. This is part of the share buyback programme as announced on 27 February 2025, for a total amount of EUR 75 million. The repurchase of shares commenced on 28 February 2025 and will be completed no later than 24 October 2025. It is intended that the shares will be cancelled following repurchase. Up to and including 11 July 2025, a cumulative total of 2,002,324 shares was repurchased under the share buyback programme for a total consideration of EUR 59,718,534. Aalberts has engaged an intermediary to repurchase the Aalberts shares in the open market, during open and closed periods, independent of Aalberts. The share buyback will...

Continue reading

Mowi ASA (OSE:MOWI): Q2 2025 Trading update

Harvest volumes Q2 2025 (1)Farming Norway 72.5 thousand tonnes  Farming Scotland 24.0 thousand tonnes  Farming Chile 15.5 thousand tonnes  Farming Canada 9.5 thousand tonnes  Farming Ireland 5.0 thousand tonnes  Farming Faroes 4.5 thousand tonnes  Farming Iceland (Arctic Fish) 2.0 thousand tonnes  Total 133.0 thousand tonnes  In connection with the presentation of the Q1 2025 results, Mowi guided a total harvest volume of 130k GWT for Q2 2025 (110k GWT in Q2 2024). Note:(1) The harvest volumes are provided in gutted weight equivalents (GWT). Additional information Operational EBIT for the Group was approx. EUR 189 million in Q2 2025 (NOK 2,206 million / EURNOK 11.67) on strong cost performance. Blended farming cost was EUR 5.39 per kg in the quarter, down from EUR 5.84 in Q2 2024 and EUR 5.89 in Q1 2025. Total...

Continue reading

Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule

SAN JOSE, Calif., July 14, 2025 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company dedicated to advancing patient care through transformative urology solutions, today announced that Aquablation therapy was assigned a Category I code effective January 1, 2026. The 2026 Medicare Proposed Physician Fee Schedule (PFS) includes payment rates for a new Category I Current Procedural Terminology (CPT) code related to Aquablation therapy. Category I CPT code 52XX1 will replace Category III CPT code 0421T as the primary code for Aquablation therapy. “Securing a Category I CPT Code marks a major milestone for PROCEPT, the urology community, and the patients we serve,” said Sham Shiblaq, chief commercial officer of PROCEPT BioRobotics. “This transition recognizes the clinical value...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.